Physician profile
Gregory Scott Usdan
NPI 1932264520
$4,984.29
in general payments reported to CMS, 2019-2025
13 companies · $472 in 2025
The $472 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $524 · 2021: $583 · 2022: $998 · 2023: $519 · 2024: $777 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,472.98 | 2019-2024 | Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $705.99 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $673.90 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Harrow Eye, LLC | $364.88 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $311.71 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $189.61 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $72.71 | 2023-2024 | Cequa |
| Allergan, INC. | $53.38 | 2020-2022 | |
| Shire North American Group INC | $38.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.52 | 2019-2021 | |
| Abbvie INC. | $27.46 | 2022 | |
| Eyevance Pharmaceuticals LLC | $21.85 | 2022 | |
| Spark Therapeutics, INC. | $20.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Usdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.